NMRA
Neumora Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$1.31
−2.96%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +20.2%
- EBIT
- +20.2%
- EPS
- +21.7%
- Free cash flow
- +7.7%
- Operating cash flow
- +7.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +44.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- +4.0%
- EBIT
- +8.5%
- Net income
- +2.8%
- EPS
- +5.2%
- Free cash flow
- -12.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026